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The factors that lead to PTS are not fully understood.
Venous hypertension caused by a persistent venous obstruc-
tion, valve incompetence, or a combination of both is con-
sidered to be the major cause of PTS.5,7-9 Not only does the
deep system seem to be important in the development of
clinical signs, but the superficial system does as well.10-12
Former studies of the natural history of acute DVT
have reported that lysis begins soon after thrombus for-
mation and continues through at least the first 6
months.13-15 Not only lysis is reported, but also propaga-
tion and recurrence,13-16 both during the acute phase16,17
and several months later.13-15 It is becoming clear that
thrombus evolution is a dynamic process, with recanaliza-
tion and further thrombotic events occurring as compet-
ing processes.18
Duplex ultrasound scan is an accurate method for
measuring compressibility, the presence of flow, and reflux
and may be used for the follow-up of patients with
DVT.17,19,20 Venous plethysmography provides additional
information regarding the functional level of the outflow
obstruction.19
The follow-up period in most studies regarding the
natural history of DVT is limited to a year or less.13-
16,18,19,21,22 The initial signs of PTS seem to develop in
most patients within the first 12 to 24 months,2 although
the more severe clinical signs, such as ulceration, usually
take a longer period to develop. This study describes the
The long-term clinical course of deep venous throm-
bosis (DVT) may be complicated by recurrent DVT and
the development of the post-thrombotic syndrome (PTS).
The clinical signs of this chronic syndrome may vary, from
scarcely visible skin changes to pain and recurrent ulcera-
tions that, in rare cases, can lead to amputation.1 During
a period of approximately 2 years, PTS develops in 10% of
the patients with a first episode of proximal DVT.2 This
number increases to 30% after 5 years.3
The risk of developing recurrent DVT within 19
months is about 10%,4 and the risk increases to about 17%
within 2 years, with a gradual increase to 24% to 30% after
≥8 years.3,5 Thus, the clinical consequences of PTS are
considerable. The prevention is not only justified on clin-
ical grounds but also on economic grounds.6
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Objective: The development of the post-thrombotic syndrome (PTS) and recurrence of deep venous thrombosis (DVT) are
not yet fully understood. The aim of the study was to identify factors that lead to the long-term complications of DVT.
Methods: In a 2-year prospective follow-up study, duplex scanning and strain-gauge plethysmography were used to evaluate
DVT in relation to the development of long-term complications. Each of the 12 segments examined was assigned as a
thrombosis score (TS). A total TS was calculated for each leg. Patent segments were assigned a TS = 0, noncompressible
vein segments with flow TS = 1 and noncompressible vein segments without flow TS = 2. The degree of resolution of DVT
and the incidence, timing, and outcome of further thrombotic events were measured during 24 months of follow-up.
Results: The study involved 86 legs with DVT. The 2-year follow-up was completed for 70 legs. Within 3 months, only
1% of the originally occluded proximal deep vein segments were still occluded. Between all time intervals, from month
12 to month 24, for example, thrombus regression continued in 36% of the legs and thrombus propagation continued
in 27%. Multiple regression analysis revealed that an increase in age (P = .008) and proximal location of the original
DVT (P = .05) was significantly related to thrombus propagation. Multiple regression analysis showed that the risk fac-
tors for clinical signs of PTS were a high venous outflow resistance after 1-month and 12-month follow-ups (P ≤ .002)
and a high thrombosis score in the proximal veins after 3 months (P = .008).
Conclusions: In the follow-up of older patients and patients with proximal DVT, evolution was shown to be an unsta-
ble process with continuing propagation for 2 years. The risk factors for the development of PTS were a slow decrease
in venous outflow resistance or a high thrombosis score of the proximal veins after 3 months. (J Vasc Surg
2001;34:649-55.)
degree of resolution of DVT in 24 months and the inci-
dence, timing, and outcome of further thrombotic events.
The purpose of the study was to evaluate the determinants
leading to the long-term complications of DVT.
METHODS
Between 1995 and 1998, all patients with acute DVT
diagnosed in the radiology department who gave
informed consent were included in the study. The study
was approved by the ethics committee of the hospital. At
the vascular laboratory, the detailed baseline examination
used in the follow-up was performed within 1 to 5 days
after diagnosis.
All patients were prospectively included in a follow-up
program and treated with heparin (65/86, 76%) or low-
molecular–weight heparin (21/86, 24%), administered for
at least 5 days during the acute phase, which was continued
until the simultaneously started treatment with oral antico-
agulation (OAC) resulted in an international normalized
ratio (INR) of between 2 and 3 during 2 consecutive days.
Patients were treated for 3 months, except the patients
with pulmonary embolism or continuing risk factors (such
as malignancy), who were treated for a longer period. The
OAC therapy was continued for 3 months in 50% (43/86)
of patients, for 6 months in 22% (19/86), for 1 year in 9%
(8/86), and for 24 months in 9% (16/86). Adequate anti-
coagulation therapy was defined as an INR value of 2 or
more within 4 days after the diagnosis.
Initially, compression therapy was applied for at least 5
days, until the leg showed no edema. At this time, gradu-
ated compression stockings were custom-made, and all
patients were instructed and motivated each visit to wear
the stockings for at least 1 year. A complete medical his-
tory was obtained. The evaluated thrombotic risk factors
were immobilization, malignancy, factor V mutation,
surgery, and pregnancy or recent delivery.
A physician, blinded to the findings of the duplex
scanning and plethysmography, quantified PTS in the
patients, 1 year and 2 years after DVT, according to the 7-
point Clinical, Etiologic, Anatomic, and Pathophysiologic
(CEAP) scale (range, 0-6) of the Ad Hoc Committee on
Reporting Standards in Venous Disease, the update.23 In
the evaluation, the 2-year CEAP score was preferably
used; if the patient did not complete the 2 year follow-up,
the 1-year CEAP score was used.
Recurrent DVT was reported if the patients had new
clinical signs of DVT and if this could be independently
confirmed by showing a new thrombus through using
phlebography or compression ultrasound scanning in the
radiology department.
Duplex ultrasound scanning. Duplex scanning was
performed, as described before,20 by two experienced vascu-
lar technicians using a Toshiba SSA 270A scanner (Tokyo,
Japan) with a 3.75-MHz or 5-MHz probe in low-flow set-
ting (minimal measurable velocity, 2 cm/s).
At the vascular laboratory, the detailed baseline exami-
nation used in the follow-up was performed within 1 to 5
days after diagnosis. The next examinations were scheduled
for 1, 3, 6, 12, and 24 months after diagnosis. Of the con-
tralateral asymptomatic leg, no follow-up was performed.
The examination was performed with the patient in
45-degree half-upright position, with the knees flexed and
the feet resting on a footstool. The 12 vein segments
examined were the common femoral vein, the superficial
femoral vein (proximal and middle), the long saphenous
vein (proximal, middle, and distal), the popliteal vein, the
short saphenous vein, and the posterior and anterior tibial
veins. In the calf, each artery is accompanied by two veins.
The two veins were numbered, one being the most super-
ficial vein and two being the deeper vein.
In the longitudinal plane, the presence of a Doppler
signal was measured. In the proximal veins, a spontaneous
Doppler signal is usually present. In the distal veins, a
Doppler signal was considered to be present if a flow sig-
nal developed after squeezing the extremity below the
level of the measurement. The compressibility was assessed
in the transverse plane. The κ coefficient of the interob-
server variability in the classification of compressibility was
0.77, as evaluated before.20 The patients were scanned by
a vascular technician blinded to the results of the previous
examinations.
Thrombosis score. The definition of the thrombus
score (TS) assigned to each segment was based on the sys-
tem modified from Porter et al.23 Patent vein segments
were assigned the TS of 0. A vein was considered fully
patent if a Doppler signal was present and the vein was
completely compressible with gentle pressure applied by
the duplex probe to the overlying skin. DVT was consid-
ered nonocclusive if the vein segment was noncompress-
ible with a Doppler signal present (TS = 1). DVT was
considered occlusive if the vein segment was noncom-
pressible and no Doppler signal was found (TS = 2).
For each leg, the TS values were calculated by adding
the TS of all 12 vein segments (TStotal). The TS was sepa-
rately scored for the four proximal deep vein segments
(common femoral, superficial femoral [proximal and mid-
dle], and popliteal veins, TSprox), the four distal deep vein
segments (two posterior and two anterior tibial, TSdist), and
the four superficial vein segments (long saphenous vein
[proximal, middle, and distal] and short saphenous, TSsup).
Propagation was reported when the observed TStotal
increased, regression when the TStotal decreased, and no
change when the TStotal remained the same during the
involved time intervals.
Strain-gauge plethysmography. The venous outflow
resistance (VOR) in both extremities was measured by
strain-gauge plethysmography as described previously.24-26
The patients were examined in supine position with pneu-
matic cuffs around the thighs of both legs and strain-
gauges around the calves. After the cuffs are inflated, the
venous volume increases. When the maximum volume was
reached, the cuff pressure was released, resulting in a vol-
ume decrease measured by plethysmography. The tangent
to the slope of the volume decrease was measured 0.5 sec-
onds after pressure release, and the slope was converted
into a venous flow rate. This procedure was performed at
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five different cuff pressures. The corresponding venous
flow rates were plotted against the effective cuff pressures.
The best slope of the line through the points gave an angle
β and, in analogy with Ohm’s law, was used to estimate the
VOR as 1/tangent β. A VOR exceeding 0.8 mm
Hg/min/% was considered abnormal.25,26 The repro-
ducibility of the VOR was within 10%, as shown before.24
Statistical evaluation. Statistics concerning the TS
were performed after logarithmic transformation to obtain
normality.
Changes during different time intervals at follow-up
concerning TStotal and VOR were compared by using the
paired t test.
The Pearson product moment correlation coefficient
between the VOR and the TStotal was calculated.
The following risk factors were tested by using multi-
ple regression analysis to explain changes in TS (propaga-
tion): age, sex, presence of malignancies (yes/no),
location of original DVT (proximal/distal), duration of
OAC therapy and adequacy of treatment (yes/no).
To explain the CEAP score at 24 months, the same risk
factors plus the TSprox, TSdist, Tssup, and TStotal and VOR
at each time interval were tested by using multiple regres-
sion.
The difference in resolution of the proximal and distal
veins was studied using the combined results of a paired t
test in patients with both proximal and distal DVT and the
unpaired t test for the rest of the patients. The only three
patients with DVT in two different legs were considered
statistically independent because the time interval between
the DVT in both legs was more that 1 year.
A P value ≤.05 was considered statistically significant.
RESULTS
In the study, 86 legs of 83 patients with proven DVT
were included (Table I). The mean age of the patients was
53 (range, 17-88; SD, 16), 43 were male, 40 female. Of
the 83 patients, 11 (13%) had previous DVT. In three of
those patients (4%), the previous DVT was located in the
same leg. Thrombosis was unilateral on the right side in
34 (41%) patients, unilateral on the left side in 46 (55%)
patients, and bilateral in 3 (4%) patients.
Individual risk factors for the initial DVT were immo-
bilization in 17 patients, malignancy in 13 patients, factor
V mutation in 13 patients, surgery in 4 patients, and
recent delivery in 3 patients. In 33 (40%) patients, no risk
factors were found.
The mean age of the 16 patients who did not com-
plete the study was 63 years (range, 30-82; SD, 16); seven
were male, and nine were female. Of these 16 patients,
seven (44%) had previous DVT. Thrombosis was unilateral
on the right side in seven patients (44%) and on the left
side in nine patients (56%). The most common risk factor
was malignancy, in six (38%) of the patients.
The distribution of the DVT by the standardized exam-
ination of all vein segments at baseline was as follows. Sixty-
eight legs with proximal DVT were found. In 26 (38%)
legs, not only proximal DVT, but also superficial thrombo-
JOURNAL OF VASCULAR SURGERY
Volume 34, Number 4 Haenen et al 651
sis were found. In eight (44%) of the remaining 18 legs,
thrombosis was found in the superficial veins as well.
The INR results were available in 73 patients; in 59
patients (81%), dosage regiment was adequate and
resulted in an INR ≥2 within 4 days after the diagnosis.
No major bleeding complications were encountered.
Of the patients who developed new clinical signs, such
as a swollen leg or pain, recurrent DVT was diagnosed by
the radiology department in eight patients, five in the leg
initially involved and three in the contralateral leg. Of
these eight patients, two used OAC therapy during the
recurrence of DVT. In two patients, prolonged heparin
treatment was necessary because the clinical signs wors-
ened and propagation of the DVT was diagnosed within
the first 2 weeks after the initial DVT. In one patient, non-
fatal pulmonary embolism developed 6 weeks after the 6
months of OAC treatment was ended. The cumulative
incidences of all recurrent events after 1, 3, 6, 12, and 24
months was 2, 2, 6, 9, and 11 patients, respectively.
Fig 1 shows the cumulative percentage of legs with
total resolution of the DVT over time (TStotal = 0) and for
only the proximal deep venous system (TSprox = 0). Within
3 months, only 1% of the 15% originally occluded proxi-
mal deep vein segments were still occluded.
Fig 2 shows the mean TStotal for 70 legs with proximal
DVT and 16 legs with distal DVT. Statistical analysis
showed that the mean TStotal only decreased significantly
in the first 3 months (P < .0001). The resolution of DVT
in the proximal deep vein segments showed no significant
difference with the thrombus resolution in distal deep vein
segments (P = .20). In the distal superficial vein segments,
the resolution was significantly higher than in the proxi-
mal superficial vein segments (P < .01).
Fig 3 shows the mean VOR over time for the legs with
proximal and distal thrombosis. Also, the VOR only
decreased significantly in the first 3 months (P < .0001).
The relation between the VOR and the TStotal was statis-
tically significant (correlation coefficients range, 0.28-
0.58, all P < .01).
Table II shows the number of legs with respectively no
change, regression, and propagation of the TS over time.
Propagation was common, although only a few vein seg-
ments progressed into occlusion (TS = 2); most of this
Table I. Number of patients in the study
n
Patients included initially 83
Lost to follow-up 16
Deaths 5
Other 11
Completed 2-year follow-up 67 (70 legs)
Recurrent events
In contralateral leg 3
In same leg 5
Prolonged heparin treatment 2
Nonfatal pulmonary embolism 1
propagation was the result of an increase to TS 1. All five
patients with clinical signs of recurrent DVT in the same
leg had propagation to TS 2 of the proximal deep vein
segments, although two patients with propagation to TS 2
in months 6 through 12 were asymptomatic. Propagation
developed more frequently in the deep vein segments than
in the superficial vein segments. Both propagation and
regression were present during the entire 2-year follow-up
period. After testing for the risk factors, age, sex, malig-
nancies, location of original DVT, adequate treatment,
and period of anticoagulation therapy, only older patients
(P = .008) and patients with a proximal location of the
original DVT (P = .05) showed a significant relation to
propagation of DVT.
To evaluate the determinants leading to the develop-
ment of the PTS, the relationship between the original
location of the DVT and the final CEAP score after 1 (n =
9) or 2 years shows in Table III. Of the 16 patients with
distal DVT, only four (25%) had no clinical signs of PTS.
After adjusting for age, the risk factors for a high
CEAP classification were a high VOR in month 1 (P =
.001) and month 12 (P = .002) and a high TSprox in
month 3 (P = .008).
DISCUSSION
Short-term changes. After treatment, the acute
symptoms of DVT, such as a swollen leg or pain, usually
disappear rapidly. One of the factors responsible for reso-
lution of the symptoms is the recovery of the venous out-
flow. As observed by Thomas et al,27 an occluded vein
segment (TS = 2) is bypassed by collaterals. The thrombus
can also retract to the vein wall, resulting in a recanalized
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Fig 2. Mean (+SE) total thrombosis score over time for legs with proximal DVT and legs with distal DVT.
Fig 1. Cumulative percentage of legs with complete resolution of DVT over time.
lumen (TS = 1). This study showed that the VOR
decreased significantly in the first month, revealing rapid
recovery of venous outflow. Within 3 months, most
occluded vein segments were recanalized. The most
important factor in the rapid disappearance of the acute
symptoms of DVT was, therefore, probably recanalization.
These results are comparable with those reported by the
study of van Ramshorst et al,28 who found most recanal-
ization to be confined to the first 6 weeks after the initial
DVT.
Intermediate-term changes, recurrent DVT. Symp-
tomatic DVT carries a high risk for recurrent DVT that
persists for many years.3 Recurrent DVT was reported in
17% of the patients after 2 years.3 In the present study,
16% of the patients had recurrent DVT. Recurrent DVT
may be caused by a disturbed balance between propaga-
tion and thrombus regression. The observed thrombosis
propagation in our study (approximately 25%) was much
higher than in a previous venographic study (7% in 6
months).21 This difference may be partly caused by prop-
agation in the superficial veins. These were not visualized
in the venographic study. Other studies15,17 using duplex
scanning found propagation rates that are similar to those
in our study, 26% after 3 weeks17 and 16% after 9
months.15 Propagation was even common during the first
JOURNAL OF VASCULAR SURGERY
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3 months, in which all patients received OAC therapy.
Therefore, this study corroborated the findings of oth-
ers,16,17 that propagation can appear despite adequate
treatment. Propagation in itself does not predict recur-
rence of clinical symptoms of DVT.16,17 As shown in Table
II, only the patients with propagation to TS 2 in the prox-
imal deep vein segments had clinical signs of recurrent
DVT. Fortunately, this was a relatively rare phenomenon.
Considering that age and proximal location of the original
DVT showed a significant relationship to propagation of
DVT, it is possible that older patients and patients with
proximal DVT have a higher risk of recurrent DVT.
Long-term changes. In this study, the mean TStotal
only decreased significantly in the first 3 months after
DVT, whereas former studies reported that lysis continues
for at least 6 months.13,15,28 As shown in Table II and Fig
4, regression continues until month 24. It should be real-
ized that in the mean, TS propagation was included as
well. Apparently, both thrombus propagation and throm-
bus regression were common during the entire 2-year
period. Propagation especially occurred in older patients
and in patients with proximal location of the original
DVT. This might indicate that about 30% of the (mainly
older) patients should be treated for a longer period than
the 3 months as is common now. This should be weighed
Fig 3. Mean (+SE) VOR over time.
Table II. Percentage of legs with an increase (propagation), decrease (regression), or no change in TS between the
different time intervals during the 2-year follow-up period
Change 0-1 mo 1-3 mo 3-6 mo 6-12 mo 12-24 mo
n 84 83 72 75 70
No change 8% 20% 43% 35% 37%
Regression 70% 62% 29% 30% 36%
Propagation 23% 18% 28% 35% 27%
Propagation to occlusion† 20% 3% 15% 3% 3%
Propagation to occlusion of proximal deep veins 7% 1% 5%* 3% 1%*
*All of these patients also had clinical signs of recurrent DVT in the same leg.
†TS = 2.
against the risk of bleeding. Another study29 has indicated
that some patients with a first period of idiopathic DVT
should be treated for longer than 3 months.
PTS develops in about 24 months.2 Factors that need
an extended period to develop are probably important in
this process, such as the degree of collateralization and the
development of reflux. Reflux will be the subject of a sep-
arate report. The degree of collateralization is important
for the hemodynamic severity of an obstructive venous
lesion.30 Plethysmography evaluates the hemodynamic
consequences of a combination of collateral formation and
recanalization.19 A disadvantage of plethysmography is that
it only measures the VOR caused by proximal DVT and
not that caused by distal DVT. Risk factors for a high
CEAP score were a high VOR in month 1 and month 12
and a high TSprox in month 3. The high VOR in the first
month could indicate the slow development of collaterals.
The high TSprox might be an indication for poorly recanal-
ized proximal deep vein segments. Prolonged treatment of
the patients with increased 1-month VOR or 3-month
TSprox may be advisable. Further studies are required to
compare the outcome of patients with and without an
increased 1-month VOR and high 3-month TSprox. The
high VOR after 1 year is influenced by the increasing VOR
of the patients with recurrent DVT.
Because severe long-term clinical signs caused by
superficial and distal venous pathology were reported by
others,10,12,31,32 these were also reported in this study. As
shown in this study, superficial venous thrombosis fre-
quently accompanies DVT. As found in a former study, a
significantly higher frequency of reflux was detected in ini-
tially thrombosed vein segments.33 Therefore, it can be
anticipated that reflux will also develop in these formerly
thrombosed superficial vein segments, which can be the
cause of ulceration, as reported previously.10,12
Reporting superficial pathology explains why the total
thrombosis resolution (27% after 12 months) in this study
was lower than in other studies (40%-55%13,15,21) after 6
to 12 months. If we exclude the superficial veins, the total
resolution was comparable (50% after 12 months).
The results of this study may be slightly biased because
of the selection of patients. As shown in the results, the
mean age of the 16 patients (63 years) was higher than that
of the overall patient group (53 years); also, more patients
had a malignancy (16% versus 38%). Because of their
higher age and continuing risk factor, the risk of a higher
2-year CEAP classification is probably considerable.
CONCLUSIONS
The most important risk factors in the development of
PTS were a high VOR in month 1 and a high proximal
thrombosis score in month 3.
Only in the first 3 months did the mean thrombosis
score and VOR decrease significantly. Recanalization was
a relatively fast process, considering that most of the vein
segments were recanalized within 3 months. In older
patients and patients with proximal DVT, thrombus evo-
lution was shown to be an unstable process with continu-
ing propagation for 2 years. Propagation in itself did not
predict clinical symptoms. As long as propagation did not
proceed to an occlusion of the proximal deep veins, the
patient did not have any clinical signs.
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